Sofinnova Closes Oversubscribed €82M MD Start IV Medtech Fund

TL;DR

Sofinnova Partners has closed an oversubscribed €82 million fourth vintage of its MD Start strategy, the Paris-based life sciences investor's company-creation vehicle for medtech. MD Start IV will fund the launch of six to eight new medical technology ventures across Europe and the US over the next five years, with Sofinnova's own partners embedded as founding operators rather than passive board members from day one. It matters because MD Start is one of the only strategies in European venture that treats medtech company creation as a repeatable, in-house manufacturing process rather than a one-off bet on an external founding team, and the fund's exits so far (LimFlow's up-to-$415M sale to Inari Medical, PreCARDIA's acquisition by Abiomed) give the model real evidence rather than just a good pitch.

Key Takeaways

Company creation is a distinct venture asset class, and Sofinnova is one of the few European firms running it at scale in medtech. Most VC funds wait for a founding team to show up with an idea; MD Start builds the team, the IP strategy, and the regulatory pathway internally before a company even has a name. That front-loads Sofinnova's own operating hours into every portfolio company, which is expensive and hard to staff, but it also means the fund controls its own deal flow instead of competing for it in a crowded medtech seed market.

An oversubscribed €82M raise for a company-creation vehicle is a strong signal in a medtech fundraising environment that has been anything but easy. Medtech has lagged software and even biotech in LP enthusiasm this cycle because of longer regulatory timelines and less obvious AI-driven upside. LPs re-upping past target for a studio-style fund suggests Sofinnova's MD Start III return profile (2.2x-plus in follow-on capital raised against a €63M fund) did the fundraising work that a pitch deck alone couldn't.

The step-up from MD Start III's €63M to MD Start IV's €82M is a real but disciplined increase, not a strategy change. A roughly 30% step-up keeps the fund inside the same six-to-eight-company construction model rather than ballooning check sizes or company count, which suggests Sofinnova is scaling its per-company resourcing (more capital and support per venture) rather than diluting the hands-on model that is the entire thesis.

Geographic dual-basing across Europe and the US matters more for medtech than for software. FDA and CE Mark pathways diverge enough that a medtech company built only for one market often has to redo clinical and regulatory work to enter the other. Sofinnova building MD Start IV companies for both from inception, as it did with Moon Surgical and BrightHeart, is a genuine structural advantage over funds that default to single-market company construction.

Fund Overview

Fund Name: Sofinnova MD Start IV
Fund Size: €82 million (oversubscribed close)
Stage: Company creation / inception-stage, through key clinical and operational milestones
Check Size: Not disclosed by the firm
Geography: Europe and the United States
Focus: Building new medtech companies from the ground up, pairing clinical insight, entrepreneurial talent, and Sofinnova's own operational bench
Key LPs: Not disclosed in primary materials

Why This Fund Matters

Venture-backed company creation, sometimes called the "venture studio" model, has a mixed track record when generalist funds try to bolt it onto a traditional check-writing practice. It works best when a firm has deep, narrow domain expertise and enough repetitions to have actually learned what a company at week one needs versus what a company at month eighteen needs. Sofinnova's MD Start franchise, now on its fourth fund, has that repetition: it has taken multiple cohorts of medtech companies from a whiteboard IP thesis through FDA and CE Mark clearance, and in at least two cases (LimFlow, PreCARDIA) through an acquisition.

The medtech fundraising backdrop makes the oversubscription notable. Generalist LPs have spent 2025 and 2026 chasing AI-native software and infrastructure funds, and medtech, with its multi-year regulatory timelines and less obviously AI-leveraged returns, has had to work harder for allocation. An €82M raise that came in ahead of target for a strategy this specialized and this capital-intensive per company (six to eight ventures built essentially from scratch) suggests LPs are underwriting the team's execution history specifically, not just riding a sector wave.

The follow-on capital math from MD Start III is the real proof point here. A €63M fund that seeded companies which went on to raise over €140M in follow-on financing is a strong signal that the studio model is producing companies venture-fundable enough for outside capital to want in, which is the hardest part of any studio thesis to prove. Studios frequently struggle to get third-party investors to underwrite a company they didn't build themselves; Sofinnova's MD Start portfolio appears to have cleared that bar repeatedly.

For the broader European medtech ecosystem, a well-capitalized, repeat company-creation vehicle is a meaningful piece of infrastructure. Clinicians, engineers, and scientists with a strong IP thesis but no interest in being a first-time CEO now have a credible path to a company that gets built around their science rather than forcing them to either become an operator overnight or shelve the idea.

The Team

Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, leads the firm overall and has been its public voice on the MD Start strategy, framing it as one of the only European approaches built specifically around creating medtech companies from inception rather than backing existing teams. The MD Start strategy itself is run by a dedicated partner group: Anne Osdoit, Cécile Dupont, and Mano Iyer, each holding Partner titles within MD Start, alongside Gérard Hascoët as Venture Partner and Josh Makower, MD, also serving as a venture partner to the strategy. This is a deep, medtech-specific bench rather than a generalist team dabbling in company creation, which fits the pattern of what makes studio models actually work.

Early Portfolio

MD Start's track record includes Moon Surgical, whose Maestro surgical robotics system has received both FDA and CE Mark clearance and has been used in more than 3,700 patient procedures, and BrightHeart, an AI-driven prenatal ultrasound guidance company that closed an €11 million Series A in January 2026 after its own FDA and CE Mark clearances. CorWave, a cardiac assist device company, has raised over €100 million in follow-on capital. Two exits anchor the strategy's credibility: LimFlow was acquired by Inari Medical for up to $415 million, and PreCARDIA was acquired by Abiomed. It is not yet public which specific companies will be built under MD Start IV, since the fund's mandate is to originate and construct new ventures over its five-year deployment window rather than back an existing pipeline.

What This Means for Founders

MD Start IV is not a fund to pitch with a finished deck and a cap table; it's a fund to approach with an unresolved clinical or engineering problem, a piece of IP, or deep domain expertise and no fixed idea yet of what the company looks like. Clinicians, engineers, and scientists who have identified a real unmet need but lack the operating experience, regulatory navigation, or company-building bandwidth to go it alone are the intended audience, and Sofinnova's role will be far more hands-on than a typical board seat: co-founding, staffing, and operating alongside the scientific principal from day one.

The value-add here is specific and rare: a firm with a demonstrated ability to get both FDA and CE Mark clearance across multiple companies in the same portfolio, plus a follow-on fundraising track record strong enough to have pulled in over €140M in outside capital behind MD Start III's companies. For a founder-scientist weighing whether to spend two years learning to be a CEO or partner with a studio that has already run this playbook repeatedly, MD Start IV is one of the more credible options in European medtech specifically because the fund's job is to reduce, not just fund, the operational risk of turning a clinical insight into a company.

Fund Momentum Take

The oversubscription is the headline, but the more interesting number is the follow-on multiple on MD Start III. Company-creation vehicles live or die on whether outside capital will underwrite a company the studio built, and a greater-than-2x follow-on ratio on a €63M fund is a genuinely strong result in a sector where studios more often end up funding their own portfolio indefinitely because nobody else will. That's the metric worth watching for MD Start IV, not the €82M headline number.

The risk sitting underneath this model is concentration of execution risk in a small partner group. Six to eight companies built essentially from the ground up by the same handful of partners, Osdoit, Dupont, Iyer, plus the venture partner bench, is a demanding operating cadence, and studio models tend to show cracks not in year one but in year three or four when the first cohort needs sustained attention at the same time the next cohort is being originated. Sofinnova has now run this playbook across four fund vintages, which is real evidence of institutional muscle memory, but it's worth watching whether the step-up to €82M comes with a corresponding step-up in partner bandwidth or just more capital chasing the same team.

Our bet: this is one of the more durable franchises in European medtech venture precisely because it doesn't scale the way software funds do. A studio model caps out on how many companies a small, deeply technical team can actually build well, and Sofinnova appears to be respecting that ceiling rather than chasing AUM growth for its own sake, which is the discipline that studio models most often lose as they mature.

Frequently Asked Questions

What is Sofinnova MD Start IV?
It's the fourth fund in Sofinnova Partners' MD Start strategy, an €82 million company-creation vehicle that builds new medtech companies from inception rather than investing in existing founding teams.

How does the MD Start model differ from typical VC investing?
Instead of writing a check into a company a founder already started, Sofinnova's MD Start partners originate the idea, help assemble the founding team, and take active operating roles in each company from day one, a model often described as venture company creation or a venture studio.

How many companies will MD Start IV fund?
The strategy plans to launch six to eight new medtech ventures over a five-year deployment period.

What geography does the fund target?
Companies are built for both the European and US markets from inception, addressing FDA and CE Mark pathways in parallel rather than sequentially.

What track record does the MD Start strategy have?
MD Start III, a €63 million fund, backed six companies that collectively raised more than €140 million in follow-on financing, and the broader MD Start portfolio includes two notable acquisitions: LimFlow (up to $415M by Inari Medical) and PreCARDIA (by Abiomed).

---

Have a fund closing to announce? Submit your fund here.

Need help raising capital? Check out our Fundraising Advisory services.